Genetic and subunit vaccines based on the stem domain of the equine influenza hemagglutinin provide homosubtypic protection against heterologous strains

Vaccine

Volumn 36, Issue 12, 2018, Pages 1592-1598

  Ibañez, Lorena Itatí ^a   Caldevilla, Cecilia Andrea ^a,b   Paredes Rojas, Yesica ^a   Mattion, Nora ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b Biogenesis Bago   (Argentina)

Author keywords

Conserved epitopes; Cross protection; Equine influenza virus; Hemagglutinin stem region; Lethal challenge

Indexed keywords

DNA VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; SUBUNIT VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA A; INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H3N8); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; VIRUS STRAIN; ANIMAL; CELL LINE; CROSS PROTECTION; HORSE; HORSE DISEASE; IMMUNIZATION; IMMUNOLOGY; ORTHOMYXOVIRUS INFECTION; VETERINARY MEDICINE; VIROLOGY;

ANIMALS; CELL LINE; CROSS PROTECTION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HORSE DISEASES; HORSES; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H3N8 SUBTYPE; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT PROTEINS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 85042013601     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2018.02.019     Document Type: Article

References (43)

1. Cullinane, A., Newton, J.R., Equine influenza—a global perspective. Vet Microbiol 167:1–2 (Nov. 2013), 205–214.
2. Chambers TM. A brief introduction to equine influenza and equine influenza viruses; 2014. p. 365–70.
3. Paillot, R., A systematic review of recent advances in equine influenza vaccination. Vaccines 2:4 (2014), 797–831.
4. Landolt, G.A., Equine influenza virus. Vet Clin North Am Equine Pract 30:3 (Dec. 2014), 507–522.
5. Perglione, C., Golemba, M., Torres, C., Barrandeguy, M., Molecular epidemiology and spatio-temporal dynamics of the H3N8 equine influenza virus in South America. Pathogens, 5(4), Oct. 2016, 61.
6. Wiley, D.C., Skehel, J.J., The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 56:1 (1987), 365–394.
7. Sriwilaijaroen, N., Suzuki, Y., Molecular basis of the structure and function of H1 hemagglutinin of influenza virus. Proc Jpn Acad Ser B Phys Biol Sci 88:6 (2012), 226–249.
8. Steel J, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio, vol. 1, no. 1; May 2010 p. e00018-10–e00018-10.
9. Ekiert, D.C., et al. Antibody recognition of a highly conserved influenza virus epitope. Science (80-.) 324:5924 (2009), 246–251.
10. Okuno, Y., Isegawa, Y., Sasao, F., Ueda, S., A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67:5 (May 1993), 2552–2558.
11. Throsby, M., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from Human IgM+ Memory B Cells. PLoS One, 3(12), Dec. 2008, e3942.
12. Sui, J., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:3 (Mar. 2009), 265–273.
13. Tan, G.S., Krammer, F., Eggink, D., Kongchanagul, A., Moran, T.M., Palese, P., A Pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol 86:11 (2012), 6179–6188.
14. Wang, T.T., et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog, 6(2), Feb. 2010, e1000796.
15. Ekiert, D.C., et al. A highly conserved neutralizing epitope on Group 2 influenza A viruses. Science (80-.) 333:6044 (2011), 843–850 Aug.
16. Margine, I., et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 87:19 (2013), 10435–10446.
17. Friesen, R.H.E., et al. A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci 111:1 (Jan. 2014), 445–450.
18. Corti, D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and Group 2 influenza A hemagglutinins. Science (80-.) 333:6044 (2011), 850–856.
19. Ekiert, D.C., et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489:7417 (Sep. 2012), 526–532.
20. Sagawa, H., Ohshima, A., Kato, I., Okuno, Y., Isegawa, Y., The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J Gen Virol 77:7 (1996), 1483–1487.
21. Gocnik, M., et al. Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. J Gen Virol 89:4 (2008), 958–967.
22. Bommakanti, G., et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci 107:31 (Aug. 2010), 13701–13706.
23. Bommakanti, G., et al. Design of escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 86:24 (2012), 13434–13444.
24. Krammer, F., Pica, N., Hai, R., Margine, I., Palese, P., Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87:12 (Jun. 2013), 6542–6550.
25. Laursen, N.S., Wilson, I.A., Broadly neutralizing antibodies against influenza viruses. Antiviral Res 98:3 (Jun. 2013), 476–483.
26. Krammer, F., Palese, P., Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:5 (2013), 521–530.
27. Woodland, D.L., Jump-starting the immune system: prime–boosting comes of age. Trends Immunol 25:2 (Feb. 2004), 98–104.
28. Lu, S., Heterologous prime–boost vaccination. Curr Opin Immunol 21:3 (Jun. 2009), 346–351.
29. Lunn, D.P., et al. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine 17:18 (May 1999), 2245–2258.
30. Soboll, G., et al. Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. Vet Immunol Immunopathol 94:1–2 (2003), 47–62.
31. Ault, A., et al. Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies. Vaccine 30:26 (Jun. 2012), 3965–3974.
32. Fiers, W., Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W.M., A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:10 (Oct. 1999), 1157–1163.
33. Weldon, W.C., Wang, B.-Z., Martin, M.P., Koutsonanos, D.G., Skountzou, I., Compans, R.W., Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One, 5(9), Sep. 2010, e12466.
34. Niwa, H., Yamamura, K., Miyazaki, J., Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:2 (1991), 193–199.
35. Verhelst, J., Parthoens, E., Schepens, B., Fiers, W., Saelens, X., Interferon-inducible protein Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex assembly. J Virol 86:24 (Dec. 2012), 13445–13455.
36. Reed, L.J., Muench, H., A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:3 (May 1938), 493–497.
37. Sączyńska, V., Influenza virus hemagglutinin as a vaccine antigen produced in bacteria. Acta Biochim Pol 61:3 (2014), 561–572.
38. Wang, C.-C., et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci 106:43 (2009), 18137–18142.
39. Xuan, C., Shi, Y., Qi, J., Zhang, W., Xiao, H., Gao, G.F., Structural vaccinology: structure-based design of influenza A virus hemagglutinin subtype-specific subunit vaccines. Protein Cell 2:12 (2011), 997–1005.
40. Nachbagauer, R., Krammer, F., Universal influenza virus vaccines and therapeutic antibodies. Clin Microbiol Infect 23:4 (2017), 222–228.
41. Grødeland, G., Bogen, B., Efficient vaccine against pandemic influenza: combining DNA vaccination and targeted delivery to MHC class II molecules. Expert Rev Vaccines 14:6 (2015), 805–814.
42. Yassine, H.M., et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21:9 (2015), 1065–1070.
43. Mallajosyula, V.V.A., et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci 111:25 (2014), E2514–E2523.